Compare Twist Bioscience Corp (TWST) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs VF Corp — how do they compare? Twist Bioscience Corp trades at $94.18 (market cap $5.45B), while VF Corp trades at $16.86 (market cap $6.62B). The key difference: VF Corp is the larger of the two by market cap, and VF Corp pays a 2.13% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| TWST | VFC | |
|---|---|---|
Market Cap | $5.45B | $6.62B |
Sector | Health | Consumer Cyclical |
52-Week High | $102.88 | $21.55 |
52-Week Low | $24.16 | $11.66 |
Enterprise Value | $5.37B | $10.77B |
Dividend Yield | — | 2.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $87.41, down 6.86% today, with a bullish technical outlook despite recent earnings misses. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a -19.85% net margin. Analyst consensus is strongly bullish with 11 buy ratings and a $91.63 price target, while recent news highlights AI-driven drug discovery collaborations and upcoming Q3 earnings.
The stock presents growth potential through expanding synthetic biology applications and AI partnerships, but carries significant risk from persistent losses, negative cash flow, and high valuation multiples (P/S 13.94). Investors should weigh the company's innovation trajectory against its path to profitability amid competitive biotech pressures.
VFC trades at $16.78, down 1.18% on the day, with technical indicators showing a neutral to bearish short-term bias. The company reported mixed quarterly results, beating estimates in Q3 and Q4 2025 but missing in Q1 2026, with revenue declining to $9.50 billion in 2025. Analyst sentiment is cautiously optimistic with a consensus price target of $19.33, while recent news highlights ongoing brand challenges and debt reduction efforts.
The outlook for VFC hinges on execution of its turnaround strategy, particularly revitalizing the Vans brand. Near-term catalysts include Q2 2026 earnings and continued debt management, but risks remain from weak consumer spending and competitive pressures. The stock offers potential upside to analyst targets if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
